Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Overview

About this study

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients will be recruited from those in the RKSC Dent Registry

  • Diagnostic criteria for Dent disease include:
    • LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria:
      • Hypercalciuria;
      • Kidney stones;
      • Nephrocalcinosis;
      • Hypophosphatemia;
      • Renal phosphate leak;
      • Aminoaciduria;
      • Glucosuria without diabetes mellitus;
      • Hematuria;
      • Renal insufficiency;
      • Family history with x-linked inheritance; or
    • 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.
  • Idiopathic calcium nephrolithiasis with renal phosphate leak.
  • Male patients > 18 years old.
  • History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR < 2.07 mg/dl).
  • Idiopathic calcium nephrolithiasis without renal phosphate leak.
  • Male patients > 18 years old.
  • History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR < 2.07 mg/dl).

Exclusion Criteria:

  • Exclusion for Dent disease include:
    • primary or secondary hyperparathyroidism;
    • hyperthyroidism;
    • chronic diarrhea states;
    • intake of thiazide diuretics;
    • glucocorticoids; or
    • estrogens within one month of the study.
  • Exclusion criteria for calcium stone formers include:
    • primary or secondary hyperparathyroidism;
    • hyperthyroidism;
    • estimated GFR < 40 ml/mn/1.73m^2;
    • chronic diarrhea states;
    • intake of thiazide diuretics;
    • glucocorticoids; or
    • estrogens within one month of the study.
  • Exclusion criteria include history of symptomatic or asymptomatic kidney stone disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed for enrollment

Contact information:

Julie Olson R.N., CCRP

(507)538-5995

Olson.Julie@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20118024

Mayo Clinic Footer